title: Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a Canadian cohort of individuals with glycogen storage disease, type II.
abstract: Glycogen storage disease, type II (GSDII; Pompe disease; acid maltase deficiency) is an autosomal recessive disease caused by mutations of the GAA gene that lead to deficient acid alpha-glucosidase enzyme activity and accumulation of lysosomal glycogen. Although measurement of acid alpha-glucosidase enzyme activity in fibroblasts remains the gold standard for the diagnosis of GSDII, analysis of the GAA gene allows confirmation of clinical or biochemical diagnoses and permits predictive and prenatal testing of individuals at risk of developing GSDII. We have developed a clinical molecular test for the detection of GAA mutations based on cycle sequencing of the complete coding region. GAA exons 2-20 are amplified in six independent PCR using intronic primers. The resulting products were purified and sequenced. Preliminary studies using this protocol were conducted with DNA from 21 GSDII-affected individuals from five centers across Canada. In total, 41 of 42 mutations were detected (96.7% detection rate). Mutations spanned intron 1 through exon 19 and included nine novel mutations. Haplotype analysis of recurrent mutations further suggested that three of these mutations are likely to have occurred independently at least twice. Additionally, we report the identification of the c.-32-13T>G GAA mutation in an individual with infantile variant GSDII, despite reports of this mutation being associated almost exclusively with late-onset forms of the disease. The development of a clinical molecular test provides an important tool for the management and counseling of families and individuals with GSDII, and has provided useful information about the GAA mutation spectrum in Canada.
authors.affiliation: Children's Hospital of Eastern Ontario, Canada K1H 8L1.
authors.forename: M E
authors.initials: ME
authors.lastname: McCready
authors.forename: N L
authors.initials: NL
authors.lastname: Carson
authors.forename: P
authors.initials: P
authors.lastname: Chakraborty
authors.forename: J T R
authors.initials: JT
authors.lastname: Clarke
authors.forename: J W
authors.initials: JW
authors.lastname: Callahan
authors.forename: M A
authors.initials: MA
authors.lastname: Skomorowski
authors.forename: A K J
authors.initials: AK
authors.lastname: Chan
authors.forename: F
authors.initials: F
authors.lastname: Bamforth
authors.forename: R
authors.initials: R
authors.lastname: Casey
authors.forename: C A
authors.initials: CA
authors.lastname: Rupar
authors.forename: M T
authors.initials: MT
authors.lastname: Geraghty
mesh_terms: D000483:Alleles; D004252:DNA Mutational Analysis; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006009:Glycogen Storage Disease Type II / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D009154:Mutation; D000520:alpha-Glucosidases / Q000172:deficiency / Q000235:genetics*
chemical_list: C509951:GAA protein, human; D000520:alpha-Glucosidases